Revolution Medicines Inc

Revolution Medicines operates with a strong liquidity position, as evidenced by its current ratio of 18.45 and cash and equivalents of $288.43 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. However, the company is experiencing negative cash flows, with an operating cash flow of -$160.56 million and a free cash flow of -$117.33 million. The company's profitability metrics are negative, with a return on equity of -6.72% and a return on assets of -6.08%. These figures are below the typical performance of the biotechnology industry, which is characterized by high R&D investment and long development cycles. The company reported a net loss of $116.00 million and an operating loss of $143.66 million. Revolution Medicines does not disclose segment or geographic revenue breakdowns in its latest financials, making it difficult to assess revenue concentration or geographic exposure. The company's operations are likely concentrated in the United States, as is common for biotechnology firms, but this is not explicitly stated in the available data. The company's growth trajectory is not evident from the current financial data, as revenue is reported as $0.00. The company is in the early stages of development, with no revenue-generating products yet. The outlook for the current fiscal year is not provided, but the company is expected to continue investing in R&D and clinical trials. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company has a low dilution potential, as the number of shares outstanding is the same for both basic and diluted shares. However, the company's negative cash flows and high price-to-book ratio of 18.42 suggest that it is in a high-risk, high-growth phase. Recent events include analyst estimates that show a mean price target of $180.32 and a median price target of $175.00, with a mean recommendation of 1.57 (1=strong buy, 5=strong sell). The company has received 9 strong-buy and 12 buy ratings, with no hold ratings, indicating strong investor confidence in its long-term potential despite current financial challenges.